According to the results of a new Phase 3 clinical trial (TRANSCEND-T2D-1) published in the renowned medical journal The Lancet<\/i>, the experimental drug Retatrutide<\/b> significantly reduced blood sugar levels and led to substantial weight loss in patients with type 2 diabetes. The trial of this weekly injectable medication involved adults who had not previously received other medical treatments and were attempting to control their sugar levels through diet and exercise alone.<\/p>\n
Upon completion of the 40-week study, patients receiving Retatrutide experienced a reduction in glycated hemoglobin (HbA1c \u2014 a long-term measure of blood sugar) by an average of 1.7% to 1.9%, compared to a reduction of just 0.8% in the placebo group. Furthermore, participants taking the new drug lost an average of 11.5% to 15.3% of their body weight, significantly outperforming the placebo group’s result (2.6%).<\/p>\n
Retatrutide belongs to a brand-new generation of weight loss and diabetes medications provisionally referred to as “GLP-3 agonists.” Unlike today’s widely used drugs (such as Ozempic or Wegovy), which primarily target only one or two hormonal receptors (GLP-1, or GLP-1 and GIP), Retatrutide simultaneously acts on three receptors involved in metabolism: GIP, GLP-1, and glucagon. Along with appetite suppression, the additional activation of the glucagon receptor increases the body’s energy expenditure, ultimately driving more effective weight loss.<\/p>\n
According to scientists, this triple-acting medication has the potential to revolutionize the management of type 2 diabetes, particularly for patients requiring more intensive treatment. Additional studies are currently ongoing to definitively confirm the drug’s long-term safety and efficacy.<\/p>\n